In this section
In this subsection

Cipla Sildenafil Products

Cipla has a long-standing relationship with sildenafil products, but “Cipla sildenafil” can refer to more than one thing. In the United States, Cipla USA has prescription generic sildenafil tablets. In other markets, Cipla has used product names associated with sildenafil, including historically documented brands such as Silagra. The product name, strength, dosage form, indication, and country therefore matter as much as the manufacturer name.

For users searching terms such as “Cipla Viagra,” the most important distinction is that Viagra is Pfizer’s brand name, while sildenafil is the active ingredient. A Cipla sildenafil product may be a generic version referencing Viagra in one market, but that does not make every Cipla-branded sildenafil product a Viagra-branded medicine or establish the same regulatory status in every country.

Sildenafil as an Active Ingredient

Sildenafil is a phosphodiesterase type 5 inhibitor used in prescription medicines. In the United States, one group of sildenafil tablets is labeled for erectile dysfunction, while other sildenafil formulations are labeled for pulmonary arterial hypertension. Those products share an active ingredient but are not interchangeable product references.

This matters when comparing a manufacturer’s portfolio. A user who searches only “sildenafil Cipla” may encounter a 25 mg, 50 mg, or 100 mg tablet associated with erectile-dysfunction labeling, but may also encounter a different dosage form or product intended for another indication. Product identity should always include the indication and labeling, not merely the ingredient name.

Cipla Sildenafil Products and Brand Names

The clearest currently verifiable U.S. Cipla relationship is the generic product labeled simply as Sildenafil Tablets. Current DailyMed labeling identifies Cipla USA Inc. as the packager for sildenafil tablets under ANDA 207178. The product family includes 25 mg, 50 mg, and 100 mg oral tablets.

Cipla also has historical and market-specific sildenafil brand relationships. An official Cipla annual report from 2001 listed Silagra as sildenafil tablets for erectile dysfunction. That establishes the Cipla/Silagra/sildenafil relationship historically, but it is not evidence that Silagra has the same current status in every market today.

The name Suhagra is widely associated online with Cipla sildenafil, but a sufficiently current authoritative source confirming its present regulatory and market status was not identified. For that reason, this page does not present Suhagra as a current verified product.

Cipla Sildenafil in the United States

Current DailyMed records provide a precise U.S. reference. Cipla USA sildenafil tablets are listed in three strengths:

  • 25 mg — source NDC 69097-951;
  • 50 mg — source NDC 69097-952;
  • 100 mg — source NDC 69097-953.

The DailyMed record identifies the product as a human prescription drug and lists ANDA 207178. Current labeling describes the tablets as oral sildenafil for erectile dysfunction. This is a product-specific U.S. regulatory record; it should not be generalized to overseas brands such as Silagra or to other sildenafil formulations.

Another Cipla USA sildenafil product is an oral suspension listed at 10 mg/mL under a different ANDA. Its existence illustrates why dosage form matters. A consumer comparing “Cipla sildenafil” products should not assume that tablets and an oral suspension have the same indication, labeling, or intended use merely because both contain sildenafil.

Silagra, Suhagra and Other Market-Specific Names

Silagra has a verified historical relationship to Cipla and sildenafil through Cipla’s own archived corporate material. That makes it reasonable to explain the name on a reference page, especially for users who encounter older packaging, search results, or historical articles. The correct description, however, is historical unless current registration in the relevant country is separately verified.

Suhagra appears frequently in third-party commercial material, but those sellers are not authoritative sources for current product registration. Without a sufficiently current authoritative source establishing its exact present market status, no claim is made here that Suhagra is currently marketed, approved, or available in a particular jurisdiction.

This is also why a market-specific brand should not be described as “FDA approved” merely because sildenafil is an FDA-approved active ingredient. FDA approval attaches to specific U.S. drug applications and products.

Product Strengths and Forms

For current U.S. Cipla sildenafil tablets labeled for erectile dysfunction, the verified strengths are 25 mg, 50 mg, and 100 mg. These are oral tablets. The current Cipla USA DailyMed record also provides NDC information and product characteristics that can help identify the exact U.S. generic.

Cipla USA also has sildenafil in an oral-suspension product. That product has a different dosage form and a separate regulatory record. A product search should therefore capture at least five identifiers:

  • active ingredient;
  • strength or concentration;
  • dosage form;
  • packager or manufacturer;
  • country and regulatory record.

Those details are more useful than relying on color, packaging style, or an old product photograph, all of which may change.

How to Verify a Cipla Sildenafil Package

For a pre-purchase or prescription-access question, the fastest way to reduce ambiguity is to compare the package against an authoritative product record. On a U.S. package, look for the generic name, strength, NDC, labeler or packager, and prescription status. A current Cipla USA package should be traceable to the corresponding DailyMed or FDA record rather than only to an online seller description.

The product markings can also help distinguish a known U.S. generic from a market-specific brand, but markings should be used with the full label rather than as a standalone identification method. Repackagers can place an approved source product into different package configurations, so the source NDC and label information matter more than a photograph found through image search.

For a non-U.S. brand such as Silagra, use the national regulator for the country named on the package. The fact that Cipla historically manufactured a sildenafil brand with that name does not establish that a package offered today is current, authentic, or registered in the buyer’s jurisdiction. Manufacturer name, market, product registration, and actual package details should all align.

Why “Cipla Viagra” Is an Inexact Search Term

“Cipla Viagra” is understandable search language because Viagra is the best-known sildenafil brand, but it mixes a manufacturer search with a different company’s brand name. In current U.S. labeling, Cipla USA’s product is identified as sildenafil tablets rather than Viagra. The reference-brand relationship helps explain the generic category; it does not transfer Pfizer’s trademark to the Cipla product.

That distinction is commercially useful when comparing prices or availability. A pharmacy may quote a generic sildenafil product, a branded Viagra product, or another manufacturer’s generic. The active ingredient can be the same while manufacturer, NDC, package size, appearance, and cash price differ. Asking for the exact manufacturer and NDC avoids using “Viagra” as a catch-all label for every sildenafil tablet.

Regulatory Status and Market Availability

In the United States, the current DailyMed record for Cipla USA sildenafil tablets identifies an ANDA and an active prescription-drug label. That is a strong product-specific reference. It does not establish the status of every Cipla sildenafil brand sold outside the United States.

Overseas brands must be checked in the regulator database for the market in which they are supplied. A brand can be legitimately registered in one country and absent from another. Packaging can also differ by market. For that reason, descriptions such as “available worldwide,” “legal in the USA,” or “approved in Europe” are not useful unless tied to the exact product and jurisdiction.

Pharmacy availability is narrower still. A product can have a valid regulatory record and still not be stocked by a particular pharmacy. This reference page is not a live inventory statement for Paulsen’s Pharmacy.

Comparing Cipla Sildenafil Products

A practical comparison should start with the objective product details rather than the best-known brand name.

  • Ingredient: confirm sildenafil rather than a similarly named medicine.
  • Strength: compare the labeled strength, not tablet size or package color.
  • Form: tablet and oral suspension are different product forms.
  • Brand or generic identity: a Cipla USA generic labeled “sildenafil” is not the same product identity as an overseas Silagra package.
  • Indication: confirm whether the product label is for erectile dysfunction or another sildenafil indication.
  • Market: use the regulator applicable to the country where the product is supplied.
  • Regulatory record: match NDC, application, registration, or equivalent identifiers where available.

For prescription access, those distinctions are more useful than trying to decide whether one brand name is universally “better.” The label and current regulatory record establish what the product actually is.

More About Cipla

This page focuses on sildenafil rather than Cipla’s broader company portfolio. For manufacturer-level information, therapeutic areas, and navigation to other Cipla product groups, see Cipla Limited.

Users comparing PDE5-inhibitor products from the same manufacturer may also find the separate reference on Cipla tadalafil products useful. Sildenafil and tadalafil are different active ingredients, and their product names, indications, labeling, and market status should be compared separately.

Reviewed by: Dr. Nancy Ann Curosh